Citations (23)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (7)
Henriette Farkas, Márta Lídia Debreczeni & Kinga Viktória Kőhalmi. (2018) Investigational drugs in phase I and phase II clinical trials for hereditary angioedema. Expert Opinion on Investigational Drugs 27:1, pages 87-103.
Read now
Read now
M Aamir Ali & Marie L Borum. (2014) Hereditary angioedema: what the gastroenterologist needs to know. Clinical and Experimental Gastroenterology 7, pages 435-445.
Read now
Read now
Enrique L Larghi & Teodoro S Kaufman. (2014) Modulators of complement activation: a patent review (2008 – 2013). Expert Opinion on Therapeutic Patents 24:6, pages 665-686.
Read now
Read now
Henriette Farkas. (2013) Current pharmacotherapy of bradykinin-mediated angioedema. Expert Opinion on Pharmacotherapy 14:5, pages 571-586.
Read now
Read now
Murat Bas¸. (2012) Clinical efficacy of icatibant in the treatment of acute hereditary angioedema during the FAST-3 trial. Expert Review of Clinical Immunology 8:8, pages 707-717.
Read now
Read now
Jonathan A. Bernstein & Joseph J. Moellman. (2012) Progress in the Emergency Management of Hereditary Angioedema: Focus on New Treatment Options in the United States. Postgraduate Medicine 124:3, pages 91-100.
Read now
Read now
Henriette Farkas & Lilian Varga. (2011) Ecallantide is a novel treatment for attacks of hereditary angioedema due to C1 inhibitor deficiency. Clinical, Cosmetic and Investigational Dermatology 4, pages 61-68.
Read now
Read now
Articles from other publishers (16)
V. Michael Holers. (2023) Complement therapeutics are coming of age in rheumatology. Nature Reviews Rheumatology 19:8, pages 470-485.
Crossref
Crossref
Zenichi Ikeda, Taku Kamei, Yusuke Sasaki, Matthew Reynolds, Nozomu Sakai, Masato Yoshikawa, Michiko Tawada, Nao Morishita, Douglas R. Dougan, Chien-Hung Chen, Irena Levin, Hua Zou, Masako Kuno, Naoto Arimura, Yusuke Kikukawa, Mitsuyo Kondo, Kimio Tohyama & Kenjiro Sato. (2023) Discovery of a Novel Series of Potent, Selective, Orally Available, and Brain-Penetrable C1s Inhibitors for Modulation of the Complement Pathway. Journal of Medicinal Chemistry 66:9, pages 6354-6371.
Crossref
Crossref
Johannes P. M. van de Mortel, Shirley D’Sa, Alexander F. J. E. Vrancken, Nicolette C. Notermans, Josephine M. I. Vos & Monique C. Minnema. (2022) Polyneuropathy Associated with IgM Monoclonal Gammopathy; Advances in Genetics and Treatment, Focusing on Anti-MAG Antibodies. Hemato 3:4, pages 663-688.
Crossref
Crossref
Gui-Hua Gong, Shu Han, Xiao-Ling Huang, Li-Ping Xie, Wei Zhang, Lei Xu & You-Jia Hu. (2021) The Expression of Recombinant Human Serum Albumin in the Mammary Gland of Transgenic Mice. Pharmaceutical Fronts 03:01, pages e30-e37.
Crossref
Crossref
Dimitrios C. Mastellos, Daniel Ricklin & John D. Lambris. (2019) Clinical promise of next-generation complement therapeutics. Nature Reviews Drug Discovery 18:9, pages 707-729.
Crossref
Crossref
Joshua M. Thurman, Ashley Frazer-Abel & V. Michael Holers. (2017) Review: The Evolving Landscape for Complement Therapeutics in Rheumatic and Autoimmune Diseases. Arthritis & Rheumatology 69:11, pages 2102-2113.
Crossref
Crossref
Mignon T. van den Elzen, Harmieke van Os-Medendorp, Heike Röckmann-Helmbach, Els van Hoffen, Ans F.M. Lebens, Helma van Doorn, Rob J.B. Klemans, Carla A.F.M. Bruijnzeel-Koomen, C. Erik Hack, Leonard Kaufman, Anurag Relan & André C. Knulst. (2016) Allergenicity and safety of recombinant human C1 esterase inhibitor in patients with allergy to rabbit or cow's milk. Journal of Allergy and Clinical Immunology 138:2, pages 476-481.e1.
Crossref
Crossref
Ayan Mukherjee, Wiebke Garrels, Thirumala R. Talluri, Daniela Tiedemann, Zsuzsanna Bősze, Zoltán Ivics & Wilfried A. Kues. (2016) Expression of Active Fluorophore Proteins in the Milk of Transgenic Pigs Bypassing the Secretory Pathway. Scientific Reports 6:1.
Crossref
Crossref
Dumitru Moldovan, Jonathan A Bernstein & Marco Cicardi. (2015) Recombinant replacement therapy for hereditary angioedema due to C1 inhibitor deficiency. Immunotherapy 7:7, pages 739-752.
Crossref
Crossref
Henriette Farkas, Kinga Viktoria Kohalmi, Nora Veszeli, Zsuzsanna Zotter & Lilian Varga. (2015) Successful prophylaxis with recombinant human C1 inhibitor in a patient with hereditary angioedema. Annals of Allergy, Asthma & Immunology 114:1, pages 64-65.
Crossref
Crossref
Lawrence M. Lewis. (2013) Angioedema: Etiology, Pathophysiology, Current and Emerging Therapies. The Journal of Emergency Medicine 45:5, pages 789-796.
Crossref
Crossref
V. Michael Holers. (2013) Human C3 glomerulopathy provides unique insights into complement factor H–related protein function. Journal of Clinical Investigation 123:6, pages 2357-2360.
Crossref
Crossref
Y.‐Y. Xu, L. V. Buyantseva, N. S. Agarwal, K. Olivieri, Y.‐X. Zhi & T. J. Craig. (2013) Update on treatment of hereditary angioedema. Clinical & Experimental Allergy 43:4, pages 395-405.
Crossref
Crossref
Getaw Worku Hassen, Hossein Kalantari, Monica Parraga, Roger Chirurgi, Carlos Meletiche, Christopher Chan, Jacque Ciarlo, Farhad Gazi, Christopher Lobaito, Siamak Tadayon, Selamawit Yemane & Carolina Velez. (2013) Fresh Frozen Plasma for Progressive and Refractory Angiotensin-Converting Enzyme Inhibitor-induced Angioedema. The Journal of Emergency Medicine 44:4, pages 764-772.
Crossref
Crossref
C. Erik Hack, Anurag Relan, Aartie Baboeram, Beatrijs Oortwijn, Serge Versteeg, Ronald van Ree & Rienk Pijpstra. (2013) Immunosafety of Recombinant Human C1-Inhibitor in Hereditary Angioedema: Evaluation of IgE Antibodies. Clinical Drug Investigation 33:4, pages 275-281.
Crossref
Crossref
Marco CicardiHenriette FarkasLilian Varga. 2012. Current and Emerging Options for Hereditary Angioedema Management. Current and Emerging Options for Hereditary Angioedema Management
32
45
.